Biotech Opportunities And Risks In Q2 – And Beyond
After a challenging first quarter of 2021 for biotech investors, what does the second quarter – and, beyond that, the second half of 2021 –…
davidgoldstein
Select Stocks For The Semiconductor Shortage
There’s a severe shortage of semiconductors – the worst shortage in 30 years according to one analysis – and it’s being felt across many industries,…
How To Approach “Extraordinarily Risky” Clinical-Stage Biotech Stocks
“Investing in any kind of stock can be risky. But investing in clinical-stage biotech stocks can be extraordinarily risky,” acknowledge the authors of today’s article.…
Wall Street Is “Pounding The Table” On This Sector – 5 Picks For Aggressive Investors
“With West Texas Intermediate (WTI) crude trading near the $60 a barrel level, and expected to go even higher this summer, these could all have…
A Stock Screen For Superior Returns With Earnings Yield At The Core
In screening for stocks with the potential of generating solid returns, the author of today’s article uses a high earnings yield as their primary criterion,…
A Focus On Next-Generation Brain Surgery Could Make This Stock A No-Brainer
The company featured in today’s article is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain – and…
Don’t Run Scared From The Recent Sell-Off In Small And Micro-Cap Stocks – Pounce On It!
“Scared money runs and misses out on profits, while smart money is always poised to pounce on temporary disconnects,” declares the author of today’s article…
Real Potential In These Artificial Intelligence Stocks
“As corporate budgets start to thaw this year along with a gradually reopening economy, AI applications are expected to receive plenty of attention,” notes the…
A Recently Approved Label Expansion Could Expand This Pain Management Stock’s Horizons
Amid the ongoing opioid crisis, the need for non-opioid pain management solutions is increasing. As a provider of pre- and post-surgical non-opioid pain management solutions,…
Is This Biopharma Company With A Unique Business A Buy?
With a portfolio currently comprised of 45 commercial products and five developmental-stage candidates in various areas, including rare disease and neurology, the company featured in…